The vaqta market research report is one of a series of new reports that provides vaqta market statistics, including the vaqta industry's global market size, regional shares, competitors with a vaqta market share, detailed vaqta market segments, market trends and opportunities, and any further data you may need to thrive in the vaqta industry. This vaqta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing global awareness of hepatitis prevention, expanding immunization programs, rising travel to endemic areas, rising government initiatives for mandatory vaccinations, growing healthcare infrastructure in developing countries, and heightened investments in vaccine research and development. Major trends in the forecast period include advancements in vaccine formulations, development of combination vaccines, enhanced cold chain logistics, advancements in vaccine delivery technologies, and adoption of needle-free delivery systems.
The increasing number of hepatitis A cases is expected to drive the growth of the vaqta market. Hepatitis A is a highly contagious viral infection affecting the liver, caused by the hepatitis A virus (HAV). Several factors, such as poor sanitation and hygiene, outbreaks within communities, unvaccinated populations, foodborne outbreaks, and environmental conditions, contribute to the rise in hepatitis A cases. The Vaqta vaccine plays a significant role in preventing the spread of the virus, particularly in high-risk areas. For example, in February 2024, the European Centre for Disease Prevention and Control reported that 30 European countries documented 4,548 hepatitis A cases in 2022, compared to 3,919 cases in 2021. This rise in hepatitis A cases is propelling the demand for vaqta.
The increasing prevalence of chronic diseases is also expected to contribute to the growth of the vaqta market. Chronic diseases are long-term conditions that require ongoing medical management or limit daily activities. The growing prevalence of chronic diseases can be attributed to aging populations, unhealthy lifestyles, and improved detection and diagnosis. Vaqta plays a vital preventive role, especially for individuals with chronic conditions who may be at greater risk for hepatitis A. For those with liver-related diseases or weakened immune systems, the vaccine is essential in preventing further liver damage and managing health risks. In September 2023, the World Health Organization reported that chronic diseases cause 74% of all global deaths, with 41 million deaths each year, including 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. This increase in chronic disease prevalence is driving demand for vaqta.
Rising healthcare expenditure is expected to further fuel the growth of the vaqta market. Healthcare expenditure refers to the total spending on health services and products over a specific period, usually measured annually. The growth in healthcare spending is driven by factors such as aging populations, increasing chronic diseases, medical advancements, and better access to healthcare. Higher healthcare spending improves access to Vaqta by supporting vaccination programs and expanding preventive care initiatives. For example, in May 2024, the Office for National Statistics in the UK reported that healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. This rise in healthcare expenditure is contributing to the growth of the vaqta market.
The key company operating in the vaqta market is Merck & Co. Inc.
North America was the largest region in the vaqta market in 2024. The regions covered in vaqta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaqta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaqta is a vaccine designed to prevent hepatitis A, a viral infection that affects the liver. As an inactivated (killed) virus vaccine, it contains a virus that has been rendered inactive, so it cannot cause the disease but instead stimulates the immune system to protect against future infections. Vaqta is a safe and effective vaccine that reduces the risk of liver disease caused by the hepatitis A virus.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vaqta include hepatitis A vaccination, travel vaccination, and routine vaccination. Hepatitis A vaccination is a preventive measure that protects individuals from the hepatitis A virus (HAV), a contagious virus that primarily targets the liver. The vaccine is intended for various age groups, including pediatrics, adults, and the elderly. Distribution channels encompass hospitals, clinics, retail pharmacies, and specialty pharmacies. End users include hospitals, clinics, ambulatory care facilities, and home care settings.
The vaqta market consists of sales of hepatitis A vaccine, combination vaccines, and vaccine adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing global awareness of hepatitis prevention, expanding immunization programs, rising travel to endemic areas, rising government initiatives for mandatory vaccinations, growing healthcare infrastructure in developing countries, and heightened investments in vaccine research and development. Major trends in the forecast period include advancements in vaccine formulations, development of combination vaccines, enhanced cold chain logistics, advancements in vaccine delivery technologies, and adoption of needle-free delivery systems.
The increasing number of hepatitis A cases is expected to drive the growth of the vaqta market. Hepatitis A is a highly contagious viral infection affecting the liver, caused by the hepatitis A virus (HAV). Several factors, such as poor sanitation and hygiene, outbreaks within communities, unvaccinated populations, foodborne outbreaks, and environmental conditions, contribute to the rise in hepatitis A cases. The Vaqta vaccine plays a significant role in preventing the spread of the virus, particularly in high-risk areas. For example, in February 2024, the European Centre for Disease Prevention and Control reported that 30 European countries documented 4,548 hepatitis A cases in 2022, compared to 3,919 cases in 2021. This rise in hepatitis A cases is propelling the demand for vaqta.
The increasing prevalence of chronic diseases is also expected to contribute to the growth of the vaqta market. Chronic diseases are long-term conditions that require ongoing medical management or limit daily activities. The growing prevalence of chronic diseases can be attributed to aging populations, unhealthy lifestyles, and improved detection and diagnosis. Vaqta plays a vital preventive role, especially for individuals with chronic conditions who may be at greater risk for hepatitis A. For those with liver-related diseases or weakened immune systems, the vaccine is essential in preventing further liver damage and managing health risks. In September 2023, the World Health Organization reported that chronic diseases cause 74% of all global deaths, with 41 million deaths each year, including 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. This increase in chronic disease prevalence is driving demand for vaqta.
Rising healthcare expenditure is expected to further fuel the growth of the vaqta market. Healthcare expenditure refers to the total spending on health services and products over a specific period, usually measured annually. The growth in healthcare spending is driven by factors such as aging populations, increasing chronic diseases, medical advancements, and better access to healthcare. Higher healthcare spending improves access to Vaqta by supporting vaccination programs and expanding preventive care initiatives. For example, in May 2024, the Office for National Statistics in the UK reported that healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. This rise in healthcare expenditure is contributing to the growth of the vaqta market.
The key company operating in the vaqta market is Merck & Co. Inc.
North America was the largest region in the vaqta market in 2024. The regions covered in vaqta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaqta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaqta is a vaccine designed to prevent hepatitis A, a viral infection that affects the liver. As an inactivated (killed) virus vaccine, it contains a virus that has been rendered inactive, so it cannot cause the disease but instead stimulates the immune system to protect against future infections. Vaqta is a safe and effective vaccine that reduces the risk of liver disease caused by the hepatitis A virus.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vaqta include hepatitis A vaccination, travel vaccination, and routine vaccination. Hepatitis A vaccination is a preventive measure that protects individuals from the hepatitis A virus (HAV), a contagious virus that primarily targets the liver. The vaccine is intended for various age groups, including pediatrics, adults, and the elderly. Distribution channels encompass hospitals, clinics, retail pharmacies, and specialty pharmacies. End users include hospitals, clinics, ambulatory care facilities, and home care settings.
The vaqta market consists of sales of hepatitis A vaccine, combination vaccines, and vaccine adjuvants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vaqta Market Characteristics4. Vaqta Market Trends And Strategies5. Vaqta Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vaqta Pricing Analysis & Forecasts30. Global Vaqta Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vaqta Market32. Recent Developments In The Vaqta Market
3. Vaqta Market Biologic Drug Characteristics
6. Global Vaqta Growth Analysis And Strategic Analysis Framework
8. Vaqta Market Segmentation
9. Global Vaqta Epidemiology Of Clinical Indications
10. Vaqta Market Regional And Country Analysis
11. Asia-Pacific Vaqta Market
12. China Vaqta Market
13. India Vaqta Market
14. Japan Vaqta Market
15. Australia Vaqta Market
16. South Korea Vaqta Market
17. Western Europe Vaqta Market
18. UK Vaqta Market
19. Germany Vaqta Market
20. France Vaqta Market
21. Eastern Europe Vaqta Market
22. North America Vaqta Market
23. USA Vaqta Market
24. Canada Vaqta Market
25. South America Vaqta Market
26. Middle East Vaqta Market
27. Africa Vaqta Market
28. Vaqta Market Competitive Landscape And Company Profiles
29. Global Vaqta Market Pipeline Analysis
33. Vaqta Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vaqta Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vaqta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vaqta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaqta market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Hepatitis A Vaccination; Travel Vaccination; Routine Vaccination2) By Age Group: Pediatrics; Adults; Elderly
3) By Distribution Channel: Hospital And Clinics; Retail Pharmacies; Specialty Pharmacies
4) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
